Core Biogenesis uses plant-based expression systems for the very large-scale and high-quality bioproduction of pharmaceutical-grade recombinant proteins. The latter are used as growth factors (GF) in synthetic cell culture media f...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto SEB
Duración del proyecto: 24 meses
Fecha Inicio: 2022-12-16
Fecha Fin: 2024-12-31
Líder del proyecto
CORE BIOGENESIS
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
2M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Core Biogenesis uses plant-based expression systems for the very large-scale and high-quality bioproduction of pharmaceutical-grade recombinant proteins. The latter are used as growth factors (GF) in synthetic cell culture media for clinical and commercial scale biomanufacturing of cell therapy. The company has developed a novel advanced proprietary bioprocess integrating breakthrough innovations overcoming major technical issues of plant systems by offering a 25-fold yield increase and a 10-fold cost reduction. Its biomanufacturing platform will enable Core Biogenesis to fully exploit the great potential of plants for large and scalable production capacity as plants are well known to be the most promising system for production upscaling.
Core Biogenesis’s ambition is to position itself as the European leader in plant-based biomanufacturing by 2025.